openPR Logo

Press Releases from NMS Group - Nerviano Medical Sciences (3 total)

SARI ANNOUNCES CLOSING OF NMS ACQUISITION

Nerviano (Milano - IT), March 28, 2018 – SARI, a Chinese market-leader biotech investment company, is pleased to announce that it has closed the previously announced agreement to acquire the 90% interests in NMS Group S.p.A., effective from today. SARI is an affiliate of Shanghai Advanced Research Institute, focused on investment in cutting-edge bio-technology and life-science opportunities, especially targeted cancer therapy. The oncology innovation is the mission of NMS Group S.p.A..

SARI, a Chinese market-leader biotech investment company, today announced it has …

Nerviano (Milano), December 27, 2017 - SARI, a Chinese market-leader biotech investment company, today announced it has entered into an agreement to acquire the 90% interests in Group NMS (NMS). Headquartered in Nerviano, near Milano, Italy, NMS is a group of fully integrated companies owned by Regione Lombardia through Fondazione Regionale per la Ricerca Biomedica, focused on oncology drug discovery, preclinical research, clinical development and manufacturing. “The NMS Group is

Nerviano Medical Sciences presents data regarding a potent new cytotoxic molecul …

NMS-P945 is a potent, innovative and proprietary cytotoxic molecule in the nms pipeline, highly suited to conjugation with targeted antibodies. At the 7th World Summit focused on ADCs (San Diego, CA), Nerviano Medical Sciences presented new data regarding the immunoconjugate drugs field, an area of intense interest in the Oncology R&D sector. During the event NMS researchers described the targeted anticancer effects obtained in preclinical models with an ADC obtained

Go To Page:   1 2 3 4 5 6 7 8 9 10